Review of the Treatment of Restless Legs Syndrome: Focus on Gabapentin Enacarbil

被引:4
作者
Burke, Rachel A. [1 ]
Faulkner, Michele A. [1 ]
机构
[1] Creighton Univ, Sch Pharm & Hlth Profess, Omaha, NE 68178 USA
关键词
restless legs syndrome; RLS; gabapentin enacarbil; Horizant; dopamine agonists;
D O I
10.4137/JCNSD.S9107
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
The FDA approved gabapentin enacarbil in 2011 as the first non-dopaminergic agent for the treatment of restless legs syndrome (RLS) symptoms. Although gabapentin enacarbil is a pro-drug of gabapentin, its pharmacokinetics differ. Absorption of gabapentin enacarbil is more predictable, and inter-patient variability in bioavailability is lower than that of gabapentin. Studies have demonstrated superiority of gabapentin enacarbil compared to placebo. Comparisons to currently available RLS treatments are lacking, but clinical trials demonstrate comparable improvement in RLS symptoms to the dopamine agonists ropinirole and pramipexole, which are usually considered first-line therapy for daily RLS symptoms. Gabapentin enacarbil was well tolerated in clinical trials. The role of the drug in RLS treatment remains undefined, although it will likely be used as an alternative for refractory RLS when other treatments have failed. Additionally, gabapentin enacarbil may be recommended for patients with daily RLS symptoms that are less intense or are associated with pain as an alternative to dopamine agonists.
引用
收藏
页码:147 / 156
页数:10
相关论文
共 64 条
[1]   Restless Leg Syndrome Associated with Olanzapine: A Case Series [J].
Aggarwal, Shilpa ;
Dodd, Seetal ;
Berk, Michael .
CURRENT DRUG SAFETY, 2010, 5 (02) :129-131
[2]   Ropinirole decreases periodic leg movements and improves sleep parameters in patients with restless legs syndrome [J].
Allen, R ;
Becker, PM ;
Bogan, R ;
Schmidt, M ;
Kushida, CA ;
Fry, JM ;
Poceta, JS ;
Winslow, D .
SLEEP, 2004, 27 (05) :907-914
[3]   Physician-diagnosed restless legs syndrome in a large sample of primary medical care patients in western Europe: Prevalence and characteristics [J].
Allen, Richard P. ;
Stillman, Paul ;
Myers, Andrew J. .
SLEEP MEDICINE, 2010, 11 (01) :31-37
[4]   Restless legs syndrome: diagnostic criteria, special considerations, and epidemiology - A report from the restless legs syndrome diagnosis and epidemiology workshop at the National Institutes of Health [J].
Allen, RP ;
Picchietti, D ;
Hening, WA ;
Trenkwalder, C ;
Walters, AS ;
Montplaisi, J .
SLEEP MEDICINE, 2003, 4 (02) :101-119
[5]   Restless legs syndrome prevalence and impact - REST general population study [J].
Allen, RP ;
Walters, AS ;
Montplaisir, J ;
Hening, W ;
Myers, A ;
Bell, TJ ;
Ferini-Strambi, L .
ARCHIVES OF INTERNAL MEDICINE, 2005, 165 (11) :1286-1292
[6]   Restless legs syndrome - A review of clinical and pathophysiologic features [J].
Allen, RP ;
Earley, CJ .
JOURNAL OF CLINICAL NEUROPHYSIOLOGY, 2001, 18 (02) :128-147
[7]  
[Anonymous], 2011, HOR PACK INS
[8]   Efficacy of Gabapentin Enacarbil vs Placebo in Patients with Postherpetic Neuralgia and a Pharmacokinetic Comparison with Oral Gabapentin [J].
Backonja, Miroslav M. ;
Canafax, Daniel M. ;
Cundy, Kenneth C. .
PAIN MEDICINE, 2011, 12 (07) :1098-1108
[9]   Iron status and neural functioning [J].
Beard, JL ;
Connor, JR .
ANNUAL REVIEW OF NUTRITION, 2003, 23 :41-58
[10]   Suicidality in People Taking Antiepileptic Drugs What is the Evidence? [J].
Bell, Gail S. ;
Mula, Marco ;
Sander, Josemir W. .
CNS DRUGS, 2009, 23 (04) :281-292